<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02913521</url>
  </required_header>
  <id_info>
    <org_study_id>P130021</org_study_id>
    <nct_id>NCT02913521</nct_id>
  </id_info>
  <brief_title>Bioequivalence Study With Clinical Endpoint for Diclofenac Sodium Topical Gel 1%</brief_title>
  <official_title>A Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Three-Arm, Multi-Site Study to Evaluate the Clinical Equivalence of Diclofenac Sodium Topical Gel 1% (Hi-Tech Pharmacal Co., Inc.) With Voltaren® Gel (Diclofenac Sodium Topical Gel) 1% (Novartis) in Patients With Osteoarthritis of the Knee</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Akorn, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Akorn, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Three-Arm, Multi-Site Study&#xD;
      to Evaluate the Therapeutic Equivalence of Diclofenac Sodium Topical Gel 1% (Hi-Tech&#xD;
      Pharmacal Co., Inc.) With Voltaren® Gel (Diclofenac Sodium Topical Gel) 1% (Novartis) in&#xD;
      Patients With Osteoarthritis of the Knee&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2015</start_date>
  <completion_date type="Actual">June 2016</completion_date>
  <primary_completion_date type="Actual">April 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Change From Baseline to Week 8 in WOMAC Pain Scale, Bioequivalence of Test to Reference.</measure>
    <time_frame>8 weeks</time_frame>
    <description>WOMAC = Western Ontario and McMaster Universities Arthritis Index. The higher number is more pain. Change from baseline to Week 8 as indicated in the title. Scale is 5 questions with a scale of 0-4, higher number is more pain. Therefore, if you have 5 questions and the max score for each is 4, the maximum number on the scale is 20 (5 questions x 4 units on the scale = 20).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>An Evaluation to Determine Superiority of Test and Reference Against Placebo in the Mean Change From Baseline to Week 8 in the Total WOMAC Pain Score.</measure>
    <time_frame>8 weeks</time_frame>
    <description>WOMAC = Western Ontario and McMaster Universities Arthritis Index. The higher number is more pain. Change from baseline to Week 8 as indicated in the title. Scale is 5 questions with a scale of 0-4, higher number is more pain. Therefore, if you have 5 questions and the max score for each is 4, the maximum number on the scale is 20 (5 questions x 4 units on the scale = 20).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidences of Treatment Emergent Adverse Events</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidences of Abnormal Vital Signs</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinically Significant Changes From Baseline in Physical Examination Results</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">934</enrollment>
  <condition>Osteoarthritis, Knee</condition>
  <arm_group>
    <arm_group_label>Diclofenac Sodium Gel 1%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Apply 4 g of gel to the knee four times a day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Voltaren Gel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Apply 4 g of gel to the knee four times a day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Apply 4 g of gel to the knee four times a day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Diclofenac Sodium Gel 1%</intervention_name>
    <arm_group_label>Diclofenac Sodium Gel 1%</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Voltaren Gel</intervention_name>
    <arm_group_label>Voltaren Gel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Ambulatory male and non-pregnant females 35 years and older diagnosed with&#xD;
             osteoarthritis according to the American College of Rheumatology Criteria (ACR) in one&#xD;
             knee. Target knee is the one with higher level of pain.&#xD;
&#xD;
             ACR Criteria includes: Knee Pain and at least 3 of the following: age ≥ 50, stiffness&#xD;
             lasting &lt; 30 mins, bony tenderness, crepitus, bony enlargement, and no palpable&#xD;
             warmth.&#xD;
&#xD;
          2. Symptom onset of &gt; 6 Months prior to Screening for the target knee.&#xD;
&#xD;
          3. If female and of child-bearing potential, prepare to abstain from sexual intercourse&#xD;
             or use a reliable method of contraception during the study (e.g., IUD, oral,&#xD;
             transdermal, injected, implanted hormonal contraceptives or condom + spermicide).&#xD;
&#xD;
          4. Periarticular knee pain due to osteoarthritis (not bursitis, tendonitis etc.) that&#xD;
             required the use of oral or topical treatments (e.g., NSAIDs or acetaminophen).&#xD;
&#xD;
          5. Radiograph of the target knee within the previous year with a Grade 1, 2 or 3 disease&#xD;
             based upon the Kellgren-Lawrence disease severity scale.&#xD;
&#xD;
          6. After a minimum of 7-day wash out of all pain medication has Baseline pain on movement&#xD;
             score of ≥ 50mm on a 0-100-mm Visual Analogue Scale for the target knee.&#xD;
&#xD;
          7. After a minimum of 7-day wash out of all pain medication has Baseline WOMAC Pain sub&#xD;
             scale of ≥ 9 on a 5 question, 5 point (0 to 4) Likert scale for the target knee.&#xD;
&#xD;
          8. Willing and able to use only acetaminophen as rescue medication.&#xD;
&#xD;
          9. Willing and able to comply with the study requirements.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Females who are pregnant, breast feeding, or planning a pregnancy.&#xD;
&#xD;
          2. Radiograph of the target knee within the previous year with a Grade 4 score on the&#xD;
             Kellgren-Lawrence disease severity scale.&#xD;
&#xD;
          3. History of osteoarthritis in the contralateral knee requiring medication (OTC or&#xD;
             prescription) within 12 months of screening.&#xD;
&#xD;
          4. After a minimum of 7-day wash out of all pain medication has Baseline pain on movement&#xD;
             score of ≥ 20mm on a 0-100-mm Visual Analogue Scale for the contralateral knee&#xD;
             immediately prior to randomization.&#xD;
&#xD;
          5. Known history of secondary osteoarthritis (e.g. congenital, traumatic, gouty&#xD;
             arthritis) of the knee or rheumatoid arthritis.&#xD;
&#xD;
          6. Known history of other chronic inflammatory diseases, (e.g., colitis) or fibromyalgia&#xD;
             during last 5 years. Patients whose disease was diagnosed at least 5 (five) years&#xD;
             prior to screening visit and have had no known disease activity (i.e., no disease&#xD;
             related complaints nor disease treatment prescribed) since then may enter into the&#xD;
             study.&#xD;
&#xD;
          7. History of asthma, hypertension, myocardial infarction, thrombotic events, stroke,&#xD;
             congestive heart failure, impaired renal function or liver disease. Patients who have&#xD;
             had high blood pressure measured at least 2 (two) years prior to screening visit and&#xD;
             have had no disease activity (i.e., no record of hypertension or anti-hypertensive&#xD;
             treatment prescribed) for at least 2 (two) years prior to screening visit may enter&#xD;
             into the study.&#xD;
&#xD;
          8. History of coronary artery bypass graft within 6 months of screening.&#xD;
&#xD;
          9. Concomitant acetylsalicylic acid therapy other than a stable low dose used for cardiac&#xD;
             prophylaxis (max. 162 mg daily) taken for at least 3 months prior to enrollment and&#xD;
             maintained throughout the duration of the study.&#xD;
&#xD;
         10. Use of warfarin or other anticoagulant therapy within 30 days of screening.&#xD;
&#xD;
         11. Use of ACE inhibitors, cyclosporine, diuretics, lithium or methotrexate, within 30&#xD;
             days of screening or during the study.&#xD;
&#xD;
         12. Known history of gastrointestinal bleeding or peptic ulcer disease.&#xD;
&#xD;
         13. Abnormal screening clinical laboratory evaluations which the Investigator deems&#xD;
             clinically significant.&#xD;
&#xD;
         14. Known allergy to aspirin or NSAIDs.&#xD;
&#xD;
         15. Skin lesions or wounds in the affected area.&#xD;
&#xD;
         16. Significant (requiring surgery) injury or major knee surgery to either knee within six&#xD;
             months prior to screening.&#xD;
&#xD;
         17. Transaminase levels that are more than two times the upper limit of the normal range&#xD;
             at screening.&#xD;
&#xD;
         18. Any other acute or chronic illness that in the opinion of the investigator could&#xD;
             compromise the integrity of study data or place the Patient at risk by participating&#xD;
             in the study.&#xD;
&#xD;
         19. Concomitant use of corticosteroids (any formulation) or use within 30 days of study&#xD;
             randomization.&#xD;
&#xD;
         20. Receipt of any drug as part of a research study within 30 days prior to screening.&#xD;
&#xD;
         21. Previous randomization into this study.&#xD;
&#xD;
         22. Known allergy (hypersensitivity) to acetaminophen.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kalev Kask, Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>EGeen International Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Vee Family Doctor's Center OY</name>
      <address>
        <city>Paide</city>
        <zip>72713</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>OU Mai Perearstid</name>
      <address>
        <city>Parnu</city>
        <zip>85010</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>East Tallinn Central Hospital</name>
      <address>
        <city>Tallinn</city>
        <zip>10138</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West Tallinn Central Hospital</name>
      <address>
        <city>Tallinn</city>
        <zip>10617</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>East Tallinn Central Hospital</name>
      <address>
        <city>Tallinn</city>
        <zip>11312</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medicum Ltd.</name>
      <address>
        <city>Tallinn</city>
        <zip>13619</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Linna Health Cerntre</name>
      <address>
        <city>Tallinn</city>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Linnamoisa Perearstikeskus</name>
      <address>
        <city>Tallinn</city>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>OU Perearstikeskus Remedium</name>
      <address>
        <city>Tallinn</city>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pirita Family Doctors Centre</name>
      <address>
        <city>Tallinn</city>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Orthopaedic and Clinical Research Center</name>
      <address>
        <city>Tartu</city>
        <zip>50410</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr.Monika Vask Ltd.</name>
      <address>
        <city>Tartu</city>
        <zip>51014</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ltd. Elli Kahar</name>
      <address>
        <city>Tartu</city>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Association of Health Centres, Medical Centre &quot;OLVI&quot;</name>
      <address>
        <city>Daugavpils</city>
        <zip>LV-5410</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>D.Saulites-Kandevicas private practice</name>
      <address>
        <city>Liepaja</city>
        <zip>LV3401</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SIS Klinika ALma</name>
      <address>
        <city>Riga</city>
        <zip>LV-1010</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Health Center 4</name>
      <address>
        <city>Riga</city>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>InMedica</name>
      <address>
        <city>Kaunas</city>
        <zip>LT-48259</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JSC Vita Longa</name>
      <address>
        <city>Kaunas</city>
        <zip>LT-48426</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JSC Saules seimos medicinos centras</name>
      <address>
        <city>Kaunas</city>
        <zip>LT-49449</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JSC Mano Seimos Gydytojas</name>
      <address>
        <city>Klaipeda</city>
        <zip>LT-94231</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Private Doctor Family Clinic JSc Ausveja</name>
      <address>
        <city>Vilnius</city>
        <zip>LT-09108</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Chamber in Warsaw Nr 5718455</name>
      <address>
        <city>Warsaw</city>
        <state>Mazovia</state>
        <zip>00-341</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CERMED</name>
      <address>
        <city>Bialystok</city>
        <zip>15-270</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ClinicMed Badurski i Wspolnicy Spolka Jawna</name>
      <address>
        <city>Bialystok</city>
        <zip>15-879</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Luke's hospital in Bielsko-Biala</name>
      <address>
        <city>Bielsko-Biala</city>
        <zip>43-300</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Private medical practice Jacek Niski</name>
      <address>
        <city>Czestochowa</city>
        <zip>I04/118</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Niepubliczny Zaklad Opieki Zdrowotnej ORTMED sp. z o.o.</name>
      <address>
        <city>Lodz</city>
        <zip>91-498</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Best Solutions</name>
      <address>
        <city>Lublin</city>
        <zip>20-059</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ZOZ w Olawie</name>
      <address>
        <city>Olawa</city>
        <zip>55-200</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MEDICOME Sp. z o.o.</name>
      <address>
        <city>Oswiecim</city>
        <zip>32-600</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Medyczne Luxmed, Przezmierowo</name>
      <address>
        <city>Poznan</city>
        <zip>60-773</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>&quot;REUMA TIKA- Centrnrn Reurnatologii&quot; NZOZ</name>
      <address>
        <city>Warsaw</city>
        <zip>02-69 l</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spiratul Judetean de Urgenta Bacau</name>
      <address>
        <city>Bacau</city>
        <zip>600114</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spital Judetean De Urgenta Bacau</name>
      <address>
        <city>Bacau</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duo Medical</name>
      <address>
        <city>Bucharest</city>
        <zip>010584</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>S.C. lanuli Med Consult Str Intr Lt. Dumitru Lemnea</name>
      <address>
        <city>Bucharest</city>
        <zip>010976</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr Ion Stoia Rheumatology Center</name>
      <address>
        <city>Bucharest</city>
        <zip>020983</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emergency County Hospital SF Gheorghe</name>
      <address>
        <city>Bucharest</city>
        <zip>520064</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>RK Medcenter SRL</name>
      <address>
        <city>Iasi</city>
        <zip>700127</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>S.C. Clinica Somesan</name>
      <address>
        <city>Marasti</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ploiești Municipal Hospital</name>
      <address>
        <city>Ploiesti</city>
        <zip>100337</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Communal Institution &quot;Cherkasy Regional Hospital of Cherkasy Regional Council&quot;</name>
      <address>
        <city>Cherkasy</city>
        <zip>18009</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Institution &quot;Ukrainian State Scientific and Research Institute of Medical and Social Problems of Disability of the Ministry of Health of Ukraine</name>
      <address>
        <city>Dnipropetrovsk</city>
        <zip>49027</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Institution &quot;Professor M.I. Sytenko Institute of Spine and Joint Patholo of the National Academ of Medical Sciences of Ukraine</name>
      <address>
        <city>Kharkiv</city>
        <zip>61024</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Communal Institution of Kyiv Regional Council &quot;Kyiv Regional Clinical Hospital&quot;</name>
      <address>
        <city>Kyiv</city>
        <zip>04107</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Institution D.F.Chebotariov Institute of Gerontology of NAMS of Ukraine</name>
      <address>
        <city>Kyiv</city>
        <zip>04114</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Institution D.F.Chebotariov Institute ofGerontolo!.!v ofNAMS of Ukraine - Dept of Age related changes to Muscoskeletal system</name>
      <address>
        <city>Kyiv</city>
        <zip>04114</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Communal Institution of.Lviv Regional Council &quot;Yu. Lypa Lviv Regional Hospital of Disabled War Veterans and Former Political Prisoners&quot;</name>
      <address>
        <city>Lviv</city>
        <zip>79495</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Odesa Regional Clinical Hospital</name>
      <address>
        <city>Odesa</city>
        <zip>65025</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MI Pyogrov Vinnystya Regional Clinical Hospital</name>
      <address>
        <city>Vinnytsya</city>
        <zip>21018</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Estonia</country>
    <country>Latvia</country>
    <country>Lithuania</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>Ukraine</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>September 22, 2016</study_first_submitted>
  <study_first_submitted_qc>September 22, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 23, 2016</study_first_posted>
  <results_first_submitted>August 12, 2020</results_first_submitted>
  <results_first_submitted_qc>February 25, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">February 26, 2021</results_first_posted>
  <last_update_submitted>February 25, 2021</last_update_submitted>
  <last_update_submitted_qc>February 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diclofenac</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 21, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/21/NCT02913521/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Diclofenac Sodium Gel 1%</title>
          <description>Apply 4 g of gel to the knee four times a day&#xD;
Diclofenac Sodium Gel 1%</description>
        </group>
        <group group_id="P2">
          <title>Voltaren Gel</title>
          <description>Apply 4 g of gel to the knee four times a day&#xD;
Voltaren Gel</description>
        </group>
        <group group_id="P3">
          <title>Placebo</title>
          <description>Apply 4 g of gel to the knee four times a day&#xD;
Placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="316"/>
                <participants group_id="P2" count="312"/>
                <participants group_id="P3" count="306"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="263"/>
                <participants group_id="P2" count="262"/>
                <participants group_id="P3" count="261"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="53"/>
                <participants group_id="P2" count="50"/>
                <participants group_id="P3" count="45"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Diclofenac Sodium Gel 1%</title>
          <description>Apply 4 g of gel to the knee four times a day&#xD;
Diclofenac Sodium Gel 1%</description>
        </group>
        <group group_id="B2">
          <title>Voltaren Gel</title>
          <description>Apply 4 g of gel to the knee four times a day&#xD;
Voltaren Gel</description>
        </group>
        <group group_id="B3">
          <title>Placebo</title>
          <description>Apply 4 g of gel to the knee four times a day&#xD;
Placebo</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="263"/>
            <count group_id="B2" value="262"/>
            <count group_id="B3" value="261"/>
            <count group_id="B4" value="786"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <population>ITT population described below</population>
          <units>year</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58" spread="10.3"/>
                    <measurement group_id="B2" value="58" spread="11.1"/>
                    <measurement group_id="B3" value="57" spread="10.8"/>
                    <measurement group_id="B4" value="57.3" spread="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <population>ITT population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="200"/>
                    <measurement group_id="B2" value="193"/>
                    <measurement group_id="B3" value="190"/>
                    <measurement group_id="B4" value="583"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="63"/>
                    <measurement group_id="B2" value="69"/>
                    <measurement group_id="B3" value="71"/>
                    <measurement group_id="B4" value="203"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean Change From Baseline to Week 8 in WOMAC Pain Scale, Bioequivalence of Test to Reference.</title>
        <description>WOMAC = Western Ontario and McMaster Universities Arthritis Index. The higher number is more pain. Change from baseline to Week 8 as indicated in the title. Scale is 5 questions with a scale of 0-4, higher number is more pain. Therefore, if you have 5 questions and the max score for each is 4, the maximum number on the scale is 20 (5 questions x 4 units on the scale = 20).</description>
        <time_frame>8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Diclofenac Sodium Gel 1%</title>
            <description>Apply 4 g of gel to the knee four times a day&#xD;
Diclofenac Sodium Gel 1%</description>
          </group>
          <group group_id="O2">
            <title>Voltaren Gel</title>
            <description>Apply 4 g of gel to the knee four times a day&#xD;
Voltaren Gel</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Apply 4 g of gel to the knee four times a day&#xD;
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline to Week 8 in WOMAC Pain Scale, Bioequivalence of Test to Reference.</title>
          <description>WOMAC = Western Ontario and McMaster Universities Arthritis Index. The higher number is more pain. Change from baseline to Week 8 as indicated in the title. Scale is 5 questions with a scale of 0-4, higher number is more pain. Therefore, if you have 5 questions and the max score for each is 4, the maximum number on the scale is 20 (5 questions x 4 units on the scale = 20).</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="258"/>
                <count group_id="O2" value="255"/>
                <count group_id="O3" value="257"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.8" spread="2.1"/>
                    <measurement group_id="O2" value="6.7" spread="2.3"/>
                    <measurement group_id="O3" value="5.9" spread="2.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>An Evaluation to Determine Superiority of Test and Reference Against Placebo in the Mean Change From Baseline to Week 8 in the Total WOMAC Pain Score.</title>
        <description>WOMAC = Western Ontario and McMaster Universities Arthritis Index. The higher number is more pain. Change from baseline to Week 8 as indicated in the title. Scale is 5 questions with a scale of 0-4, higher number is more pain. Therefore, if you have 5 questions and the max score for each is 4, the maximum number on the scale is 20 (5 questions x 4 units on the scale = 20).</description>
        <time_frame>8 weeks</time_frame>
        <population>mITT</population>
        <group_list>
          <group group_id="O1">
            <title>Diclofenac Sodium Gel 1%</title>
            <description>Apply 4 g of gel to the knee four times a day&#xD;
Diclofenac Sodium Gel 1%</description>
          </group>
          <group group_id="O2">
            <title>Voltaren Gel</title>
            <description>Apply 4 g of gel to the knee four times a day&#xD;
Voltaren Gel</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Apply 4 g of gel to the knee four times a day&#xD;
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>An Evaluation to Determine Superiority of Test and Reference Against Placebo in the Mean Change From Baseline to Week 8 in the Total WOMAC Pain Score.</title>
          <description>WOMAC = Western Ontario and McMaster Universities Arthritis Index. The higher number is more pain. Change from baseline to Week 8 as indicated in the title. Scale is 5 questions with a scale of 0-4, higher number is more pain. Therefore, if you have 5 questions and the max score for each is 4, the maximum number on the scale is 20 (5 questions x 4 units on the scale = 20).</description>
          <population>mITT</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="263"/>
                <count group_id="O2" value="262"/>
                <count group_id="O3" value="261"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.8" spread="1.9"/>
                    <measurement group_id="O2" value="6.6" spread="2.0"/>
                    <measurement group_id="O3" value="5.9" spread="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidences of Treatment Emergent Adverse Events</title>
        <time_frame>8 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidences of Abnormal Vital Signs</title>
        <time_frame>8 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinically Significant Changes From Baseline in Physical Examination Results</title>
        <time_frame>8 weeks</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Diclofenac Sodium Gel 1%</title>
          <description>Apply 4 g of gel to the knee four times a day&#xD;
Diclofenac Sodium Gel 1%</description>
        </group>
        <group group_id="E2">
          <title>Voltaren Gel</title>
          <description>Apply 4 g of gel to the knee four times a day&#xD;
Voltaren Gel</description>
        </group>
        <group group_id="E3">
          <title>Placebo</title>
          <description>Apply 4 g of gel to the knee four times a day&#xD;
Placebo</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="306"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="306"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="306"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>General disorders, muscle/skeletal, and nervous system</sub_title>
                <counts group_id="E1" events="316" subjects_affected="24" subjects_at_risk="316"/>
                <counts group_id="E2" events="312" subjects_affected="20" subjects_at_risk="312"/>
                <counts group_id="E3" events="306" subjects_affected="17" subjects_at_risk="306"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>application site reaction</sub_title>
                <counts group_id="E1" events="316" subjects_affected="6" subjects_at_risk="316"/>
                <counts group_id="E2" events="312" subjects_affected="4" subjects_at_risk="312"/>
                <counts group_id="E3" events="306" subjects_affected="3" subjects_at_risk="306"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Kalev Kask</name_or_title>
      <organization>Egeen</organization>
      <phone>16504690600</phone>
      <email>kalev.kask@egeeninc.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

